Portfolio Holdings Detail for ISIN IE00BMWPV470
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares MSCI USA SRI UCITS ETF GBP Hedged (Dist)
Issuer Blackrock

ETF Ticker SUAP(GBP) LSE
ETF Ticker SUAP.LS(GBP) CXE
ETF Ticker SUAP.L(GBP) LSE

Holdings detail for ALNY

Stock Name	Alnylam Pharmaceuticals Inc
Ticker	ALNY(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US02043Q1076
LEI	529900S3ZI14OWRJII50

Show aggregate ALNY holdings

News associated with ALNY

Noteworthy ETF Outflows: XBI, MRNA, ALNY, EXEL: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $225.3 million dollar outflow -- that's a 4.6% decrease week over week - 2025-07-30 14:49:03
Y Intercept Hong Kong Ltd Has $1 Million Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Y Intercept Hong Kong Ltd lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,720 shares of the biopharmaceutical company’s stock after selling 796 shares during the period. […] - 2025-07-25 09:12:53
Victory Capital Management Inc. Cuts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Victory Capital Management Inc. lowered its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 5.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,649 shares of the biopharmaceutical company’s stock after selling 2,148 shares during the period. Victory Capital […] - 2025-07-25 08:14:50
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the twenty-six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation and twenty-two have assigned a buy recommendation to the […] - 2025-07-24 09:26:55
Alnylam Pharmaceuticals (NASDAQ:ALNY) Now Covered by Truist Financial: Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research report sent to investors on Monday, Marketbeat reports. The firm issued a buy rating and a $385.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts also recently issued reports on ALNY. Jefferies Financial […] - 2025-07-22 06:14:59
Nisa Investment Advisors LLC Cuts Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Nisa Investment Advisors LLC cut its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 38.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,155 shares of the biopharmaceutical company’s stock after selling 5,162 shares during […] - 2025-07-14 08:54:56
Crossmark Global Holdings Inc. Takes Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Crossmark Global Holdings Inc. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 1,018 shares of the biopharmaceutical company’s stock, valued at approximately $275,000. Other hedge funds have also modified their holdings of the […] - 2025-07-14 08:14:48
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Vontobel Holding Ltd.: Vontobel Holding Ltd. decreased its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 6.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,691 shares of the biopharmaceutical company’s stock after selling 113 shares during the […] - 2025-07-08 07:40:51
Mirae Asset Global Investments Co. Ltd. Sells 2,596 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Mirae Asset Global Investments Co. Ltd. reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 28.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,534 shares of the biopharmaceutical company’s stock after selling 2,596 shares during the […] - 2025-07-04 07:52:27
Wells Fargo & Company Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $333.00: Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price target lifted by research analysts at Wells Fargo & Company from $287.00 to $333.00 in a report released on Monday,Benzinga reports. The brokerage presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price objective would suggest a potential upside […] - 2025-07-02 06:05:01
Diversified Trust Co Sells 999 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Diversified Trust Co cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 40.3% in the first quarter, Holdings Channel reports. The institutional investor owned 1,482 shares of the biopharmaceutical company’s stock after selling 999 shares during the period. Diversified Trust Co’s holdings in Alnylam Pharmaceuticals were worth $400,000 as of […] - 2025-07-01 10:10:56
Sequoia Financial Advisors LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Sequoia Financial Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.0% in the first quarter, HoldingsChannel reports. The fund owned 3,395 shares of the biopharmaceutical company’s stock after acquiring an additional 99 shares during the period. Sequoia Financial Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $917,000 […] - 2025-07-01 08:22:50
Alnylam Pharmaceuticals (NASDAQ:ALNY) Sets New 12-Month High Following Analyst Upgrade: Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) hit a new 52-week high on Monday after Wells Fargo & Company raised their price target on the stock from $287.00 to $333.00. Wells Fargo & Company currently has an equal weight rating on the stock. Alnylam Pharmaceuticals traded as high as $327.05 and last […] - 2025-07-01 05:27:01
Kentucky Retirement Systems Buys New Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Kentucky Retirement Systems bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,794 shares of the biopharmaceutical company’s stock, valued at approximately $2,375,000. Several other institutional investors and […] - 2025-06-24 09:20:52
Kentucky Retirement Systems Insurance Trust Fund Makes New $1.01 Million Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Kentucky Retirement Systems Insurance Trust Fund purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 3,746 shares of the biopharmaceutical company’s stock, valued at approximately $1,011,000. Other institutional investors […] - 2025-06-24 08:20:53
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Boosted by Blue Trust Inc.: Blue Trust Inc. lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 33.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 1,158 shares of the biopharmaceutical company’s stock after acquiring an additional 293 shares during the quarter. Blue Trust Inc.’s holdings in Alnylam Pharmaceuticals were worth $313,000 at the end of […] - 2025-06-23 08:46:58
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Exchange Traded Concepts LLC: Exchange Traded Concepts LLC cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 3.1% in the 1st quarter, HoldingsChannel.com reports. The fund owned 3,715 shares of the biopharmaceutical company’s stock after selling 118 shares during the period. Exchange Traded Concepts LLC’s holdings in Alnylam Pharmaceuticals were worth $1,003,000 at the […] - 2025-06-20 08:16:56
Brighton Jones LLC Buys 177 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Brighton Jones LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 17.2% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,209 shares of the biopharmaceutical company’s stock after acquiring an additional 177 shares during the period. Brighton Jones LLC’s holdings […] - 2025-06-18 08:18:57
NorthCrest Asset Manangement LLC Makes New $323,000 Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): NorthCrest Asset Manangement LLC purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,196 shares of the biopharmaceutical company’s stock, valued at approximately $323,000. Several […] - 2025-06-16 08:36:55
JPMorgan Chase & Co. Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price: Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) had its price target lifted by JPMorgan Chase & Co. from $330.00 to $338.00 in a report released on Thursday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock. Several other brokerages also recently weighed in on ALNY. Scotiabank increased their price target […] - 2025-06-13 07:56:50
Wedmont Private Capital Grows Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Wedmont Private Capital lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 7.2% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 1,592 shares of the biopharmaceutical company’s stock after acquiring an additional 107 shares during the quarter. Wedmont Private Capital’s holdings […] - 2025-06-11 08:27:00
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Brokerages: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-six research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-one have given a buy rating […] - 2025-06-09 07:32:59
Wealth Enhancement Advisory Services LLC Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 94.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,566 shares of the biopharmaceutical company’s stock after purchasing an additional 6,112 shares during the […] - 2025-06-05 09:18:56
Yvonne Greenstreet Sells 19,297 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) CEO Yvonne Greenstreet sold 19,297 shares of the stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer now owns 48,948 shares of […] - 2025-06-05 08:12:58
Insider Selling: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Sells 31,640 Shares of Stock: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) CEO Yvonne Greenstreet sold 31,640 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $304.39, for a total value of $9,630,899.60. Following the transaction, the chief executive officer now owns 48,948 shares in the company, […] - 2025-06-05 08:12:58
Vident Advisory LLC Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Vident Advisory LLC boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 21.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 1,327 shares of the biopharmaceutical company’s stock after purchasing an additional 232 shares during the period. Vident Advisory LLC’s holdings in Alnylam Pharmaceuticals were worth $312,000 at the […] - 2025-05-29 08:28:49
Cetera Investment Advisers Grows Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY): Cetera Investment Advisers raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 66.3% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 4,770 shares of the biopharmaceutical company’s stock after acquiring an additional 1,902 shares during the quarter. Cetera Investment Advisers’ holdings in Alnylam Pharmaceuticals were worth $1,122,000 at […] - 2025-05-23 07:54:51
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $319.17 Consensus Price Target from Brokerages: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and twenty-one have assigned a buy recommendation to the company. […] - 2025-05-13 06:14:46
XBI, EXAS, ALNY, NTRA: Large Outflows Detected at ETF: Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF (Symbol: XBI) where we have detected an approximate $288.7 million dollar outflow -- that's a 5.9% decrease week over week - 2025-05-09 14:52:51
Alnylam Pharmaceuticals (NASDAQ:ALNY) Trading 4% Higher Following Analyst Upgrade: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report)’s stock price was up 4% during mid-day trading on Monday after UBS Group raised their price target on the stock from $331.00 to $349.00. UBS Group currently has a buy rating on the stock. Alnylam Pharmaceuticals traded as high as $271.09 and last traded at $269.86. Approximately […] - 2025-05-07 05:24:42

iShares MSCI USA SRI UCITS ETF GBP Hedged (Dist) ALNY holdings

Date	Number of ALNY Shares Held	Base Market Value of ALNY Shares	Local Market Value of ALNY Shares	Change in ALNY Shares Held	Change in ALNY Base Value	Current Price per ALNY Share Held	Previous Price per ALNY Share Held
2025-07-28 (Monday)	41,382	USD 13,440,460	USD 13,440,460
2025-07-25 (Friday)	41,634	USD 13,689,676	USD 13,689,676
2025-07-24 (Thursday)	41,634	USD 13,655,952	USD 13,655,952
2025-07-23 (Wednesday)	41,661	USD 13,566,488	USD 13,566,488
2025-07-22 (Tuesday)	42,081	USD 13,688,108	USD 13,688,108
2025-07-21 (Monday)	42,109	USD 13,496,777	USD 13,496,777
2025-07-18 (Friday)	42,109	USD 13,497,198	USD 13,497,198
2025-07-17 (Thursday)	42,082	USD 13,663,605	USD 13,663,605
2025-07-16 (Wednesday)	41,264	USD 13,320,432	USD 13,320,432
2025-07-15 (Tuesday)	41,480	USD 12,905,258	USD 12,905,258
2025-07-14 (Monday)	41,642	USD 13,148,462	USD 13,148,462
2025-07-11 (Friday)	41,642	USD 13,114,731	USD 13,114,731
2025-07-10 (Thursday)	41,534	USD 13,400,530	USD 13,400,530	162	USD 125,496	USD 322.64	USD 320.87
2025-07-09 (Wednesday)	41,372	USD 13,275,034	USD 13,275,034	-135	USD 96,561	USD 320.87	USD 317.5
2025-07-08 (Tuesday)	41,507	USD 13,178,473	USD 13,178,473	-736	USD -513,751	USD 317.5	USD 324.13
2025-07-07 (Monday)	42,243	USD 13,692,224	USD 13,692,224	0	USD -328,650	USD 324.13	USD 331.91
2025-07-04 (Friday)	42,243	USD 14,020,874	USD 14,020,874	0	USD 0	USD 331.91	USD 331.91
2025-07-03 (Thursday)	42,243	USD 14,020,874	USD 14,020,874	0	USD 90,400	USD 331.91	USD 329.77
2025-07-02 (Wednesday)	42,243	USD 13,930,474	USD 13,930,474	0	USD 155,454	USD 329.77	USD 326.09
2025-06-30 (Monday)	42,243	USD 13,775,020	USD 13,775,020	0	USD 137,712	USD 326.09	USD 322.83
2025-06-27 (Friday)	42,243	USD 13,637,308	USD 13,637,308	-351	USD 81,767	USD 322.83	USD 318.25
2025-06-26 (Thursday)	42,594	USD 13,555,541	USD 13,555,541	-27	USD -165,864	USD 318.25	USD 321.94
2025-06-25 (Wednesday)	42,621	USD 13,721,405	USD 13,721,405	0	USD -130,420	USD 321.94	USD 325
2025-06-24 (Tuesday)	42,621	USD 13,851,825	USD 13,851,825	-73	USD 483,053	USD 325	USD 313.13
2025-06-23 (Monday)	42,694	USD 13,368,772	USD 13,368,772	0	USD 146,440	USD 313.13	USD 309.7
2025-06-20 (Friday)	42,694	USD 13,222,332	USD 13,222,332	-552	USD -284,259	USD 309.7	USD 312.32
2025-06-19 (Thursday)	43,246	USD 13,506,591	USD 13,506,591	0	USD 0	USD 312.32	USD 312.32
2025-06-18 (Wednesday)	43,246	USD 13,506,591	USD 13,506,591	0	USD 156,118	USD 312.32	USD 308.71
2025-06-17 (Tuesday)	43,246	USD 13,350,473	USD 13,350,473	-1,160	USD -361,212	USD 308.71	USD 308.78
2025-06-16 (Monday)	44,406	USD 13,711,685	USD 13,711,685	0	USD 35,081	USD 308.78	USD 307.99
2025-06-13 (Friday)	44,406	USD 13,676,604	USD 13,676,604	-135	USD 106,298	USD 307.99	USD 304.67
2025-06-12 (Thursday)	44,541	USD 13,570,306	USD 13,570,306	130	USD 310,070	USD 304.67	USD 298.58
2025-06-11 (Wednesday)	44,411	USD 13,260,236	USD 13,260,236	0	USD -172,315	USD 298.58	USD 302.46
2025-06-10 (Tuesday)	44,411	USD 13,432,551	USD 13,432,551	0	USD -68,393	USD 302.46	USD 304
2025-06-09 (Monday)	44,411	USD 13,500,944	USD 13,500,944	-297	USD 51,436	USD 304	USD 300.83
2025-06-06 (Friday)	44,708	USD 13,449,508	USD 13,449,508	-78	USD -344,580	USD 300.83	USD 308
2025-06-05 (Thursday)	44,786	USD 13,794,088	USD 13,794,088	0	USD 120,474	USD 308	USD 305.31
2025-06-04 (Wednesday)	44,786	USD 13,673,614	USD 13,673,614	-513	USD -86,863	USD 305.31	USD 303.77
2025-06-03 (Tuesday)	45,299	USD 13,760,477	USD 13,760,477	-135	USD -146,416	USD 303.77	USD 306.09
2025-06-02 (Monday)	45,434	USD 13,906,893	USD 13,906,893	0	USD 69,514	USD 306.09	USD 304.56
2025-05-30 (Friday)	45,434	USD 13,837,379	USD 13,837,379

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ALNY by Blackrock for IE00BMWPV470

Show aggregate share trades of ALNY

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-07-10 BUY 162 322.640* 313.96
2025-07-09 SELL -135 320.870* 313.69 Profit of 42,348 on sale
2025-07-08 SELL -736 317.500* 313.54 Profit of 230,765 on sale
2025-06-27 SELL -351 322.830* 309.04 Profit of 108,475 on sale
2025-06-26 SELL -27 318.250* 308.53 Profit of 8,330 on sale
2025-06-24 SELL -73 325.000* 306.67 Profit of 22,387 on sale
2025-06-20 SELL -552 309.700* 305.99 Profit of 168,905 on sale
2025-06-17 SELL -1,160 308.710* 304.59 Profit of 353,323 on sale
2025-06-13 SELL -135 307.990* 303.75 Profit of 41,006 on sale
2025-06-12 BUY 130 304.670* 303.63
2025-06-09 SELL -297 304.000* 304.80 Profit of 90,526 on sale
2025-06-06 SELL -78 300.830* 305.79 Profit of 23,852 on sale
2025-06-04 SELL -513 305.310* 304.93 Profit of 156,429 on sale
2025-06-03 SELL -135 303.770* 306.09 Profit of 41,322 on sale
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-07-10	BUY	162	322.640*	313.96
2025-07-09	SELL	-135	320.870*	313.69 Profit of 42,348 on sale
2025-07-08	SELL	-736	317.500*	313.54 Profit of 230,765 on sale
2025-06-27	SELL	-351	322.830*	309.04 Profit of 108,475 on sale
2025-06-26	SELL	-27	318.250*	308.53 Profit of 8,330 on sale
2025-06-24	SELL	-73	325.000*	306.67 Profit of 22,387 on sale
2025-06-20	SELL	-552	309.700*	305.99 Profit of 168,905 on sale
2025-06-17	SELL	-1,160	308.710*	304.59 Profit of 353,323 on sale
2025-06-13	SELL	-135	307.990*	303.75 Profit of 41,006 on sale
2025-06-12	BUY	130	304.670*	303.63
2025-06-09	SELL	-297	304.000*	304.80 Profit of 90,526 on sale
2025-06-06	SELL	-78	300.830*	305.79 Profit of 23,852 on sale
2025-06-04	SELL	-513	305.310*	304.93 Profit of 156,429 on sale
2025-06-03	SELL	-135	303.770*	306.09 Profit of 41,322 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ALNY

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-07-30	533,885	14,703	942,788	56.6%
2025-07-29	164,268	55	384,537	42.7%
2025-07-28	150,240	69	571,965	26.3%
2025-07-25	90,782	429	298,801	30.4%
2025-07-24	132,001	11,546	286,155	46.1%
2025-07-23	184,149	63	312,340	59.0%
2025-07-22	134,761	7,553	524,612	25.7%
2025-07-21	113,303	101	243,119	46.6%
2025-07-18	84,117	9	196,317	42.8%
2025-07-17	124,319	1,178	264,381	47.0%
2025-07-16	229,664	5,440	533,124	43.1%
2025-07-15	90,523	1,040	298,338	30.3%
2025-07-14	47,280	550	196,965	24.0%
2025-07-11	115,405	249	419,301	27.5%
2025-07-10	50,212	0	113,939	44.1%
2025-07-09	184,247	12,600	379,915	48.5%
2025-07-08	159,926	1,928	339,080	47.2%
2025-07-07	271,062	215	590,864	45.9%
2025-07-03	90,643	1,034	169,761	53.4%
2025-07-02	154,249	3,951	401,624	38.4%
2025-07-01	292,605	1,103	561,088	52.1%
2025-06-30	159,979	13,384	327,105	48.9%
2025-06-27	242,267	15,227	441,752	54.8%
2025-06-26	103,504	382	262,603	39.4%
2025-06-25	152,234	1,867	243,691	62.5%
2025-06-24	192,001	15,349	458,440	41.9%
2025-06-23	121,709	969	198,647	61.3%
2025-06-20	139,701	2,405	266,158	52.5%
2025-06-18	273,642	9,342	480,294	57.0%
2025-06-17	139,053	930	245,341	56.7%
2025-06-16	103,889	343	189,090	54.9%
2025-06-13	115,399	7,296	185,970	62.1%
2025-06-12	125,197	6,567	206,790	60.5%
2025-06-11	69,425	1,360	164,486	42.2%
2025-06-10	89,373	5,562	210,150	42.5%
2025-06-09	132,281	2,258	237,654	55.7%
2025-06-06	144,697	6,519	352,673	41.0%
2025-06-05	126,194	8,386	281,334	44.9%
2025-06-04	151,375	4,597	221,629	68.3%
2025-06-03	191,466	4,025	321,821	59.5%
2025-06-02	228,085	3,656	401,798	56.8%
2025-05-30	554,449	40,011	866,494	64.0%
2025-05-29	177,868	2,532	433,288	41.1%
2025-05-28	130,900	782	420,726	31.1%
2025-05-27	109,448	16,756	303,098	36.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares MSCI USA SRI UCITS ETF GBP Hedged (Dist)
Issuer	Blackrock
ETF Ticker	SUAP(GBP) LSE
ETF Ticker	SUAP.LS(GBP) CXE
ETF Ticker	SUAP.L(GBP) LSE